<DOC>
	<DOCNO>NCT01857817</DOCNO>
	<brief_summary>The purpose study evaluate clinical benefit co-administration propranolol etodolac ( VT-122 therapy ) patient clinically progressive prostate cancer .</brief_summary>
	<brief_title>Efficacy Safety Study Etodolac Propranolol Patients With Clinically Progressive Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Etodolac</mesh_term>
	<criteria>1 . Have confirm diagnosis prostate cancer 2 . Male participant ≥18 year age 3 . In opinion investigator , participant life expectancy least 3 month . 4 . Two consecutively rise PSA value two three rise PSA value ( 2.0 ng/mL minimum end value PSA ) minimum 1week interval 5 . Have Karnofsky Performance Score ( KPS ) equal great 70 6 . Have follow laboratory parameter ( may assess locally ) : 1 . Platelet count ≥50 x 10E3/µL 2 . Total bilirubin ≤1.5 mg/dL 3 . Serum creatinine ≤1.5 x upper limit normal ( ULN ) creatinine clearance &gt; 60 mL/min calculate use CockcroftGault 4 . Liver enzymes [ aspartate transaminase ( AST ) , alanine transaminase ( ALT ) ] ≤2 x ULN 7 . Able provide write informed consent prior study specific screen procedure understand patient right withdraw study time , reason without prejudice 1 . The patient history another primary cancer , exception : 1 . Curatively resect nonmelanomatous skin cancer ; 2 . Other primary solid tumor know active disease present opinion investigator affect patient outcome set current prostate cancer diagnosis . 2 . Contraindication propranolol , etodolac 3 . Patients beta blocker 4 . Patients receive chemotherapy ( e.g. , docetaxel , cabazitaxel , taxane , platinum single agent combination ) cancer treatment 5 . History evidence cardiac disease : congestive heart failure ; New York Heart Association class 2 great ; active coronary artery disease ; unstable angina , cardiac arrhythmia require antiarrhythmic therapy , atrioventricular block second third degree , uncontrolled hypertension , patient recent ( less 6 month ) myocardial infarction ( MI ) coronary revascularization 6 . Hypotension time screen ( i.e. , systolic blood pressure le 110 mmHg . Diastolic blood pressure le 60 mmHg ) 7 . Resting heart rate le 60 bpm time screen 8 . Any uncontrolled , intercurrent illness opinion Investigator may interfere study evaluation . Participants uncontrolled diabetes exclude study . 9 . On chronotropic drug ( acetylcholine , digoxin , diltiazem , verapamil , atropine , dopamine , dobutamine , epinephrine , isoproterenol ) 10 . Active clinically serious infection [ &gt; Grade 2 National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 ] 11 . Substance abuse , medical , psychological social condition may , opinion investigator , interfere patient 's participation study evaluation study result 12 . Known suspected allergy investigational agent agent give association trial ( hypersensitivity reaction , hive , rash , difficulty breathe swell face , lip , tongue , throat ) 13 . Any condition unstable opinion Investigator could jeopardize safety patient his/her compliance study 14 . Patients uncontrolled diabetes insulin resistance 15 . Participation investigational trial receipt investigational drug device occur within 30 day prior screen study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>